ITUS Corp (NASDAQ: ITUS) provided a pleasant surprise for investors yesterday when the company announced an update surrounding their CAR-T therapy. At the moment, the company is working to drive innovation in the oncology space through the use of CAR-T therapy as a targeted treatment for solid tumor types. In particular, the company is working … Read more
ITUS Corporation (NASDAQ: ITUS) is headed up in the pre-market this morning, and for good reason. The company announced that it has selected its first commercial focus for its Cchek™ liquid biopsy platform. Of course, the news is exciting investors, sending the stock on a run for the top. Today, we’ll talk about: The first … Read more
Cancer is a devastating illness that affects a large population of patients in the United States. In fact, it is estimated by the National Cancer Institute that in the year 2018 alone, 1.73535 million patients will be diagnosed with cancer and 609,640 Americans will succumb to the ailment. However, thanks to incredible advances in the … Read more
ITUS Corp (NASDAQ: ITUS) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company provided its shareholders with a clinical update and informing them of a coming corporate update. Of course, this caused excitement among investors, leading to gains in the value of the stock. As is … Read more